Search

Displaying results 2221 - 2230 of 3734 in total
  1. Drug

    Dexamethasone acetate

    go.drugbank.com/drugs/DB14649
    ApprovedInvestigationalVet approved

    Commonly known as decadron, dexamethasone acetate is a glucocorticosteroid previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and other conditions. Developed in 1957, dexamethasone is stru...

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  2. Drug

    Melengestrol acetate

    go.drugbank.com/drugs/DB14659
    Experimental

    A 6-methyl progesterone acetate with reported glucocorticoid activity and effect on estrus.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  3. Drug

    Temsavir

    go.drugbank.com/drugs/DB14675
    Investigational

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    Cortisone

    go.drugbank.com/drugs/DB14681
    Investigational

    A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite hydrocortisone...

    Categories: Corticosteroid Hormone Receptor Agonists, Cytochrome P-450 CYP3A Inducers
  5. Drug

    Vicagrel

    go.drugbank.com/drugs/DB16349
    Investigational

    Vicagrel is under investigation in clinical trial NCT03599284 (The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  6. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

  7. Drug

    Goldenseal

    go.drugbank.com/drugs/DB16594
    Approved

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors
  8. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene. ROS1 mutations are one...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Rhodamine B

    go.drugbank.com/drugs/DB16853
    Experimental

    Categories: P-glycoprotein substrates
  10. Drug

    Tanshinone I

    go.drugbank.com/drugs/DB16886
    Experimental

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors